150 related articles for article (PubMed ID: 10399099)
1. NTBC as palliative treatment in chronic tyrosinaemia type I.
Ros J; Vilaseca MA; Lambruschini N; Mas A; Lindstedt S; Holme E
J Inherit Metab Dis; 1999 Jun; 22(5):665-6. PubMed ID: 10399099
[No Abstract] [Full Text] [Related]
2. Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC.
Bird S; Miller NJ; Collins JE; Rice-Evans CA
J Inherit Metab Dis; 1995; 18(2):123-6. PubMed ID: 7564225
[No Abstract] [Full Text] [Related]
3. Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).
Pronicka E; Rowinska E; Bentkowski Z; Zawadzki J; Holme E; Lindstedt S
J Inherit Metab Dis; 1996; 19(2):234-8. PubMed ID: 8739974
[No Abstract] [Full Text] [Related]
4. New treatment for tyrosinaemia.
Lancet; 1992 Oct; 340(8823):822-3. PubMed ID: 1357248
[No Abstract] [Full Text] [Related]
5. Promising new treatment for type I tyrosinemia.
Heubi JE
J Pediatr Gastroenterol Nutr; 1993 Oct; 17(3):340-1. PubMed ID: 8271141
[No Abstract] [Full Text] [Related]
6. NTBC and alkaptonuria.
Anikster Y; Nyhan WL; Gahl WA
Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
[No Abstract] [Full Text] [Related]
7. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
Holme E; Lindstedt S
J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
[TBL] [Abstract][Full Text] [Related]
8. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.
Lock EA; Ellis MK; Gaskin P; Robinson M; Auton TR; Provan WM; Smith LL; Prisbylla MP; Mutter LC; Lee DL
J Inherit Metab Dis; 1998 Aug; 21(5):498-506. PubMed ID: 9728330
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
10. [Favorable outcome of treatment with NTBC of acute liver insufficiency disclosing hereditary tyrosinemia type I].
Barkaoui E; Debray D; Habès D; Ogier H; Bernard O
Arch Pediatr; 1999 May; 6(5):540-4. PubMed ID: 10370811
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
Ellis MK; Whitfield AC; Gowans LA; Auton TR; Provan WM; Lock EA; Smith LL
Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701
[TBL] [Abstract][Full Text] [Related]
12. Peripheral neuropathy as the presenting feature of tyrosinaemia type I and effectively treated with an inhibitor of 4-hydroxyphenylpyruvate dioxygenase.
Gibbs TC; Payan J; Brett EM; Lindstedt S; Holme E; Clayton PT
J Neurol Neurosurg Psychiatry; 1993 Oct; 56(10):1129-32. PubMed ID: 8410015
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.
Grompe M; Overturf K; al-Dhalimy M; Finegold M
J Inherit Metab Dis; 1998 Aug; 21(5):518-31. PubMed ID: 9728332
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
Mitchell GA
Hum Exp Toxicol; 1996 Feb; 15(2):179-81. PubMed ID: 8645506
[No Abstract] [Full Text] [Related]
15. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
Kassel R; Sprietsma L; Rudnick DA
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
[No Abstract] [Full Text] [Related]
16. [Late onset type I tyrosinemia].
Klujber V; Sallai A; Kálmánchey R; Szönyi L; Hosszú E
Orv Hetil; 1997 Jul; 138(28):1805-8. PubMed ID: 9280876
[TBL] [Abstract][Full Text] [Related]
17. The role of nitisinone in tyrosine pathway disorders.
Lock E; Ranganath LR; Timmis O
Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
[TBL] [Abstract][Full Text] [Related]
18. The fate of tyrosinaemic Hungarian patients before the NTBC aera.
László A; Rózsa M; Sallay E; Tiszlavicz L; Janovszky A; Várkonyi A; Karg E; Wittmann G; Túri S; Ugarte M
Ideggyogy Sz; 2013 Nov; 66(11-12):415-9. PubMed ID: 24555242
[TBL] [Abstract][Full Text] [Related]
19. [Evolution of a case of tyrosinemia type I treated with NTBC].
Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
[TBL] [Abstract][Full Text] [Related]
20. Increased excretion of coproporphyrin I in a patient with hereditary tyrosinaemia type I: relevant changes with NTBC treatment.
Depetris-Boldini C; Galetto R; Videla MP; de Kremer Dodelson R
J Inherit Metab Dis; 1999 May; 22(3):227-30. PubMed ID: 10384374
[No Abstract] [Full Text] [Related]
[Next] [New Search]
